Data missing for daytime symptoms on 1 subject, nocturnal symptoms in 2 subjects, SABA use in 15 subjects, functional status on 12 subjects.†Only 2 subjects used omalizumab: 1 in Group 2 and 1 in Grou
aDuring follow-up, three patients made a plan for pregnancy, and all of them were in the SRVPA group.bRR = Relative risk.cDefined as the patient discontinuing SRVPA or topiramate treatment on his or h